Denise Myshko

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

COUR Pharmaceuticals is about begin a phase 1b/2a study to assess a therapy for type 1 diabetes that prevents islet cell destruction and triggers a T cell response.

Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, talks with Managed Healthcare Executive about Robert F. Kennedy Jr., President Donald Trump’s HHS secretary nominee.

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a refillable ocular implant.

The Senate Finance Committee voted 14-13 along party lines this morning to send the nomination of Robert F. Kennedy Jr. to be HHS Secretary to the full Senate.

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

In a new study, researchers found that time-in-range for healthy blood sugar could be a viable marker of glycemic control and potentially could be used to predict complications of type 1 diabetes.

At today's confirmation hearing, Democratic senators were skeptical of the HHS Secretary nominee Robert F. Kennedy Jr.'s claim that he is now pro-vaccine.

Robert F. Kennedy Jr., the HHS secretary nominee, has said he is not antivaccine, but he has a track record of casting doubt on the safety and efficacy of vaccines.

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common complication of type 2 diabetes.

Wendy Watson takes over Kaiser Foundation Health Plan and Hospitals of the Northwest, and Corwin N. Harper becomes president of Kaiser Foundation Health Plan of Georgia.

Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.

Health policy leaders say withdrawing from the WHO is a global health crisis in the making.

CEO Andrew Witty promised that UnitedHealthcare would work to speed up turnaround times for approval of some procedures and services in Medicare Advantage plans.

Ozempic, Rybelsus and Wegovy top the list of the newest drugs selected for Medicare Part D price negotiation, part of the Inflation Reduction Act.

In an investor call, Andrew Witty promised full transparency and 100% pass-through rebates for prescription drugs by 2028.

UnitedHealth Group reported a medical care ratio in 2024 of 85.5% compared with 83.2% in 2023.

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells invisible to a patient’s immune system.

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and steer patients to their own pharmacies.

Effective Jan. 1, 2025, Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an accelerated approval based on a surrogate endpoint.

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 diabetes and recommend that physicians discuss potential use of Tzield, a monoclonal antibody approved to delay the onset of the symptoms of the disease.

Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly therapy and the first specifically approved for cardiomyopathy in patients with Duchenne muscular dystrophy.

In November 2024, a regulatory advisory board said the benefits of Zynquista does not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in early January 2025 and will be priced at parity to the IV version of Opdivo.

Tryngolza is once-monthly, subcutaneous RNA-targeted therapy and is expected to be available by the end of the year with a price of $595,000.

The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.

Women are more than twice as likely to develop post-traumatic stress disorder than men, and a new study demonstrates for the first time that women have a greater inherited biological risk.

A new bill in Congress would require pass-through prices in both Medicare, and Medicaid and require transparency of PBM practices in the commercial space.

The 2024 Pharmacy Benefit Management Institute (PBMI) Annual National Conference was held Sep. 4-6 in Orlando, Florida. Managed Healthcare Executive is the official publication of the institute. Here is a sample of our coverage.